DK3448364T3 - Målretning af det iboende immunsystem med henblik på at frembringe langvarig tolerance og at opløse akkumulering af makrofager ved aterosklerose - Google Patents

Målretning af det iboende immunsystem med henblik på at frembringe langvarig tolerance og at opløse akkumulering af makrofager ved aterosklerose Download PDF

Info

Publication number
DK3448364T3
DK3448364T3 DK17790646.8T DK17790646T DK3448364T3 DK 3448364 T3 DK3448364 T3 DK 3448364T3 DK 17790646 T DK17790646 T DK 17790646T DK 3448364 T3 DK3448364 T3 DK 3448364T3
Authority
DK
Denmark
Prior art keywords
macrophages
atherosclerosis
targeting
dissolve
accumulation
Prior art date
Application number
DK17790646.8T
Other languages
Danish (da)
English (en)
Inventor
Willem Mulder
Zahi Fayad
Francois Fay
Jordi Ochando
Mounia Braza
Raphael Duivenvoorden
Original Assignee
Icahn School Med Mount Sinai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icahn School Med Mount Sinai filed Critical Icahn School Med Mount Sinai
Application granted granted Critical
Publication of DK3448364T3 publication Critical patent/DK3448364T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A61K51/1224—Lipoprotein vesicles, e.g. HDL and LDL proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1275—Lipoproteins or protein-free species thereof, e.g. chylomicrons; Artificial high-density lipoproteins [HDL], low-density lipoproteins [LDL] or very-low-density lipoproteins [VLDL]; Precursors thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
DK17790646.8T 2016-04-29 2017-05-01 Målretning af det iboende immunsystem med henblik på at frembringe langvarig tolerance og at opløse akkumulering af makrofager ved aterosklerose DK3448364T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662329676P 2016-04-29 2016-04-29
PCT/US2017/030444 WO2017190145A1 (en) 2016-04-29 2017-05-01 Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis

Publications (1)

Publication Number Publication Date
DK3448364T3 true DK3448364T3 (da) 2022-05-02

Family

ID=60161161

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17790646.8T DK3448364T3 (da) 2016-04-29 2017-05-01 Målretning af det iboende immunsystem med henblik på at frembringe langvarig tolerance og at opløse akkumulering af makrofager ved aterosklerose

Country Status (11)

Country Link
US (2) US20190290593A1 (enExample)
EP (2) EP4014967A1 (enExample)
JP (2) JP7262100B2 (enExample)
CN (2) CN116077439A (enExample)
AU (3) AU2017257189B2 (enExample)
CA (1) CA3021645A1 (enExample)
DK (1) DK3448364T3 (enExample)
ES (1) ES2913073T3 (enExample)
PL (1) PL3448364T3 (enExample)
PT (1) PT3448364T (enExample)
WO (1) WO2017190145A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190290593A1 (en) * 2016-04-29 2019-09-26 Icahn School Of Medicine At Mount Sinai Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis
EP3713547A4 (en) * 2017-11-20 2023-07-19 Icahn School of Medicine at Mount Sinai Inhibiting trained immunity with a therapeutic nanobilogic composition
BR112022000985A2 (pt) * 2019-07-19 2022-04-05 Univ Michigan Regents Composições e métodos para tratar distúrbios autoimunes
US20220409702A1 (en) * 2019-11-22 2022-12-29 The Research Foundation For The State University Of New York Compositions and methods for use in type 1 diabetes
CN111494320A (zh) * 2020-04-24 2020-08-07 上海交通大学医学院附属仁济医院 一种载糖皮质激素的纳米载体及其制备和应用
CA3187283A1 (en) * 2020-06-29 2022-01-06 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-protein s single-domain antibodies and polypeptides comprising thereof
AU2022239614A1 (en) 2021-03-19 2023-10-12 Icahn School Of Medicine At Mount Sinai Compounds for regulating trained immunity, and their methods of use
CN114788835B (zh) * 2022-04-07 2024-01-23 中山大学附属第三医院 Foxp3阳性巨噬细胞在制备治疗急性脑梗死药物中的应用

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI66878C (fi) 1978-02-24 1984-12-10 Ciba Geigy Ag Foerfarande foer framstaellning av nya antigenderivat
JPS5528933A (en) 1978-08-21 1980-02-29 Dai Ichi Seiyaku Co Ltd Muramyldipeptide dimer
JPS5618996A (en) 1979-06-21 1981-02-23 Dai Ichi Seiyaku Co Ltd Muramyldipeptide derivative
FI75578C (fi) 1979-07-25 1988-07-11 Ciba Geigy Ag Analogifoerfarande foer framstaellning av farmakologiskt verkande lipofila fosfatidylmuramylpeptider.
JPS58172399A (ja) 1982-04-05 1983-10-11 Dai Ichi Seiyaku Co Ltd ムラミルトリペプチド誘導体
EP0102319B1 (de) 1982-07-23 1987-08-19 Ciba-Geigy Ag Verwendung von Muramylpeptiden oder deren Analogen zur Prophylaxe und Therapie von Virusinfektionen
FI852105A7 (fi) 1984-05-29 1985-11-30 Ciba Geigy Ag Asyloidut sokerijohdannaiset, menetelmä niiden valmistamiseksi ja niiden käyttö.
JPS6157597A (ja) 1984-08-29 1986-03-24 Toshiyuki Hamaoka ムラミルペプチド活性エステル誘導体
EP0192609A3 (de) 1985-02-20 1988-04-27 Ciba-Geigy Ag Acylierte Hexosederivate und Verfahren zu ihrer Herstellung
EP0192611A3 (de) 1985-02-20 1988-05-11 Ciba-Geigy Ag Acylierte Hexosederivate und Verfahren zu ihrer Herstellung
US4640911A (en) 1985-05-29 1987-02-03 Ciba-Geigy Corporation Acylated sugar derivatives, processes for their manufacture, and their use
US5540931A (en) * 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
WO1993010148A1 (en) 1991-11-19 1993-05-27 Peptech (Uk) Limited Muramyl compounds for treatment of septic shock
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5349060A (en) 1993-01-07 1994-09-20 American Home Products Corporation Rapamycin 31-ester with N,N-dimethylglycine derivatives useful as immunosuppressive agents
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
GB9320820D0 (en) 1993-10-08 1993-12-01 Biokine Tech Ltd Compounds for medicinal use
ES2146741T3 (es) 1993-12-17 2000-08-16 Novartis Ag Derivados de rapamicina utiles como inmunosupresores.
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
GB9413935D0 (en) 1994-07-11 1994-08-31 Peptech Uk Ltd Use of maramyl peptide compounds
GB9419011D0 (en) 1994-09-21 1994-11-09 Peptech Uk Ltd Use of muramyl peptide compounds
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
RU2158267C2 (ru) 1995-06-09 2000-10-27 Новартис Аг Производные рапамицина и фармацевтическая композиция на их основе
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
GB9618673D0 (en) 1996-09-06 1996-10-16 Peptech Uk Ltd The use of muramyl peptides
CA2407897A1 (en) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
CA2319928A1 (en) 2000-09-18 2002-03-18 Vasogen Ireland Limited Apoptosis-mimicking synthetic entities and use thereof in medical treatments
GB0025414D0 (en) 2000-10-16 2000-11-29 Consejo Superior Investigacion Nanoparticles
US7592008B2 (en) 2000-11-20 2009-09-22 The Board Of Trustees Of The University Of Illinois, A Body Corporate And Politic Of The State Of Illinois Membrane scaffold proteins
WO2003042402A2 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
WO2004056875A1 (en) 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
CA2517839A1 (en) 2003-03-26 2004-10-07 Martin F. Bachmann Melan-a peptide analogue-virus-like-particle conjugates
KR101376715B1 (ko) 2003-12-19 2014-03-27 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 소프트 또는 임프린트 리소그래피를 이용하여 분리된 마이크로- 및 나노- 구조를 제작하는 방법
JP4224115B2 (ja) 2004-04-14 2009-02-12 ワイス ラパマイシン４２−エステル誘導体の位置特異的合成
KR100560102B1 (ko) 2004-06-25 2006-03-13 한국생명공학연구원 프로아포리포단백질 ａ－ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제
EP1768692B8 (en) 2004-07-01 2015-06-17 Yale University Targeted and high density drug loaded polymeric materials
AU2005306533B2 (en) 2004-11-17 2012-05-31 Arbutus Biopharma Corporation siRNA silencing of apolipoprotein B
DK2161336T4 (en) 2005-05-09 2017-04-24 Ono Pharmaceutical Co Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies
RS54271B1 (sr) 2005-07-01 2016-02-29 E. R. Squibb & Sons, L.L.C. Humana monoklonska antitela za ligand programirane smrti 1 (pd-l1)
WO2007022474A2 (en) 2005-08-19 2007-02-22 Cylene Pharmaceuticals, Inc. HUMAN RIBOSOMAL DNA(rDNA) AND RIBOSOMAL RNA (rRNA) NUCLEIC ACIDS AND USES THEREOF
US20090226525A1 (en) 2007-04-09 2009-09-10 Chimeros Inc. Self-assembling nanoparticle drug delivery system
CN101096386A (zh) 2007-06-05 2008-01-02 复旦大学 Dectin-1与热休克蛋白Hsp60聚合物及其编码核酸和应用
NZ582150A (en) 2007-06-18 2012-08-31 Msd Oss Bv Antibodies to human programmed death receptor pd-1
PL2214491T3 (pl) 2007-10-05 2016-11-30 Analogi chinolonów i związane z nimi sposoby
EP2620157A3 (en) 2007-10-12 2013-10-16 Massachusetts Institute of Technology Vaccine nanotechnology
CN101903018B (zh) 2007-10-17 2012-09-05 韩国科学技术院 用于递送核酸基因的ldl样阳离子纳米微粒、其制备方法以及使用其递送核酸基因的方法
US20110020242A1 (en) 2007-12-12 2011-01-27 Gang Zheng High-density lipoprotein-like peptide-phospholipid scaffold ("hpps") nanoparticles
EP2262489A2 (en) 2008-02-28 2010-12-22 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Hollow nanoparticles and uses thereof
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
WO2009158678A1 (en) 2008-06-27 2009-12-30 Children's Hospital & Research Center At Oakland Lipophilic nucleic acid delivery vehicle and methods of use therefor
MX2011003195A (es) 2008-09-26 2011-08-12 Dana Farber Cancer Inst Inc Anticuerpos anti-pd-1, pd-l1 y pd-l2 humanos y usos de los mismos.
WO2010048452A2 (en) 2008-10-22 2010-04-29 Kathryn Jill Chavez Polycyclic compounds and methods related thereto
US20120015899A1 (en) 2008-10-25 2012-01-19 Plant Bioscience, Limited Modified plant virus particles and uses therefor
HRP20170908T1 (hr) 2008-12-09 2017-09-22 F. Hoffmann - La Roche Ag Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
US9051567B2 (en) 2009-06-15 2015-06-09 Tekmira Pharmaceuticals Corporation Methods for increasing efficacy of lipid formulated siRNA
WO2011044545A2 (en) 2009-10-09 2011-04-14 Sigalov Alexander B Methods and compositions for targeted imaging
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
WO2011082400A2 (en) 2010-01-04 2011-07-07 President And Fellows Of Harvard College Modulators of immunoinhibitory receptor pd-1, and methods of use thereof
WO2011159877A2 (en) 2010-06-18 2011-12-22 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
KR101480362B1 (ko) 2010-08-23 2015-01-28 주식회사 강스템바이오텍 Ｎｏｄ２의 아고니스트를 처리한 줄기세포 또는 그 배양물을 포함하는 면역질환 또는 염증질환의 예방 또는 치료용 약학조성물
KR101253399B1 (ko) * 2010-10-26 2013-04-11 영남대학교 산학협력단 아포지단백질 ａ－ｉ 및 그 변이체를 포함한 재조합 고밀도지단백질을 이용한 라파마이신 제형
US20140086839A1 (en) 2011-03-17 2014-03-27 Tel Hashomer Medical Research Infrastructure And Services Ltd. Quinolone analogs for treating autoimmune diseases
CN102178954B (zh) 2011-04-25 2014-05-28 中国药科大学 具有血管壁靶向和逆向转运胆固醇功能的重组高密度脂蛋白载药系统及其应用
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
WO2013192310A1 (en) * 2012-06-19 2013-12-27 Massachusetts Institute Of Technology Mass production and size control of nanoparticles through controlled microvortices
EP2703384A1 (en) 2012-08-27 2014-03-05 Ludwig-Maximilians-Universität München Inhibitors of CD40-TRAF6 interaction
JP2016540042A (ja) 2013-11-05 2016-12-22 コグネート バイオサービシズ， インコーポレイテッド がんを処置するためのチェックポイント阻害剤および治療薬の組合せ
CN103589699B (zh) 2013-11-05 2015-05-13 江南大学 一种可溶性淀粉底物特异性提高的环糊精糖基转移酶
ES2754207T3 (es) 2013-11-28 2020-04-16 Tel Hashomer Medical Res Infrastructure & Services Ltd Inhibidores de la ARN polimerasa I y usos de los mismos
PT3981437T (pt) 2014-04-23 2025-01-15 Modernatx Inc Vacinas de ácidos nucleicos
US20160074473A1 (en) * 2014-07-31 2016-03-17 Kinemed, Inc. Effect of phospholipid composition of reconstituted hdl on its cholesterol efflux and anti-inflammatory properties
US10610564B2 (en) 2015-02-26 2020-04-07 Stc.Unm IRGM and precision autophagy controls for antimicrobial and inflammatory disease states and methods of detection of autophagy
EP3273944B1 (en) 2015-03-25 2024-11-20 The Regents of The University of Michigan Compositions and methods for delivery of biomacromolecule agents
US11642419B2 (en) 2015-03-25 2023-05-09 The Regents Of The University Of Michigan Compositions and methods for treating cardiovascular related disorders
WO2016155809A1 (en) 2015-03-31 2016-10-06 Biontech Rna Pharmaceuticals Gmbh Lipid particle formulations for delivery of rna and water-soluble therapeutically effective compounds to a target cell
AU2016252416A1 (en) 2015-04-20 2017-10-26 Memorial Sloan Kettering Cancer Center Imaging of tumor-associated macrophages
WO2016172615A1 (en) 2015-04-24 2016-10-27 University Of Delaware Synthetic n-acetyl-muramic acid derivatives and uses thereof
US10995140B2 (en) 2015-06-05 2021-05-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. GM-CSF/CD40L vaccine and checkpoint inhibitor combination therapy
JP2018521068A (ja) 2015-07-15 2018-08-02 セレーター ファーマシューティカルズ インコーポレイテッド 改善されたナノ粒子送達系
US20180221289A1 (en) 2015-08-06 2018-08-09 Autotelic Llc Phospholipid-cholesteryl ester nanoformulations and related methods
JP6899154B2 (ja) * 2015-12-18 2021-07-07 ノースウェスタン ユニバーシティ 一酸化窒素放出高密度リポタンパク質様ナノ粒子（ｎｏ ｈｄｌ ｎｐｓ）
US20190008918A1 (en) 2016-03-08 2019-01-10 Bioxcel Corporation Immunomodulation therapies for cancer
US20190290593A1 (en) * 2016-04-29 2019-09-26 Icahn School Of Medicine At Mount Sinai Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis
CN115028617A (zh) 2016-05-24 2022-09-09 基因泰克公司 Cbp/ep300的杂环抑制剂及其在治疗癌症中的用途
WO2018071549A1 (en) 2016-10-11 2018-04-19 New York University Nanoparticles and uses thereof
CN106831614B (zh) 2017-01-09 2020-07-28 清华大学 取代的苯并二氮杂环类化合物及其制备方法和用途
AU2018250226B2 (en) 2017-04-04 2025-04-24 Barinthus Biotherapeutics North America, Inc. Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response
EP3713547A4 (en) 2017-11-20 2023-07-19 Icahn School of Medicine at Mount Sinai Inhibiting trained immunity with a therapeutic nanobilogic composition
EP3713548A4 (en) 2017-11-21 2021-06-23 Icahn School of Medicine at Mount Sinai Promoting trained immunity with therapeutic nanobiologic compositions
KR102198900B1 (ko) 2019-05-10 2021-01-07 서강대학교 산학협력단 질병 치료용 나노입자 복합체 및 이의 제조방법
AU2022239614A1 (en) 2021-03-19 2023-10-12 Icahn School Of Medicine At Mount Sinai Compounds for regulating trained immunity, and their methods of use
JP2025511149A (ja) 2022-03-31 2025-04-15 アイカーン スクール オブ メディスン アット マウント サイナイ 免疫調節のためのスフィンゴ脂質をロードしたナノ生物製剤

Also Published As

Publication number Publication date
PL3448364T3 (pl) 2022-08-16
CA3021645A1 (en) 2017-11-02
AU2017257189B2 (en) 2022-03-31
US20230218537A1 (en) 2023-07-13
PT3448364T (pt) 2022-05-04
CN116077439A (zh) 2023-05-09
EP3448364A4 (en) 2019-12-25
AU2022204675A1 (en) 2022-09-15
WO2017190145A1 (en) 2017-11-02
EP4014967A1 (en) 2022-06-22
EP3448364B1 (en) 2022-02-09
JP2023085437A (ja) 2023-06-20
JP2019515926A (ja) 2019-06-13
ES2913073T3 (es) 2022-05-31
AU2025217324A1 (en) 2025-09-04
JP7262100B2 (ja) 2023-04-21
US12377054B2 (en) 2025-08-05
AU2017257189A1 (en) 2018-11-15
CN109640959B (zh) 2023-03-17
EP3448364A1 (en) 2019-03-06
AU2022204675B2 (en) 2025-09-04
CN109640959A (zh) 2019-04-16
US20190290593A1 (en) 2019-09-26

Similar Documents

Publication Publication Date Title
DK3448364T3 (da) Målretning af det iboende immunsystem med henblik på at frembringe langvarig tolerance og at opløse akkumulering af makrofager ved aterosklerose
IL269230A (en) Systems and methods for thermal regulation
GB201906670D0 (en) Systems and methods to detect stress allergy and thermal asymmetry
DK3560098T3 (da) Fotovoltaik-anlæg og tilhørende anvendelse
DK3409083T3 (da) Forbedringer af og i forbindelse med datacentre
DK2909808T3 (da) Forbedringer i og i forbindelse med behandling af undersøgelsesdata om en undervandsscene
DK3067575T3 (da) Skrue til undgåelse af revner og grater
DK3174976T3 (da) Fremgangsmåder og systemer til forarbejdning af partikler
DK2965479T3 (da) Fremgangsmåder og systemer til forbedret detektering af e-navigationsmeddelelser
DK3510049T5 (da) Varianter af sur alfa-glucosidase og anvendelser deraf
DK3034868T3 (da) Systemer og metoder til øgning af vindturbinekraftoutput
DK3619362T3 (da) Forbedringer af og i forbindelse med barrierer
DK3104717T3 (da) Saccharosereduktion og generering af uopløselige fibre i juice
DK3087761T3 (da) Høreapparat som kan indsættes i øregangen og høreapparatsystem
DK3380313T3 (da) Forbedringer vedrørende fremstillingen af vindmøllevinger
DK3394778T3 (da) Fremgangsmåde og system til at forbedre sikkerheden af en transaktion
EP3546765A4 (en) BRIDLE CONNECTING STRUCTURE AND BRACKET
IL259202A (en) Modified immune cells and uses thereof
DK3163069T3 (da) Vindturbine-montagesystem og tilhørende fremgangsmåde
DK3042669T3 (da) Antitumormiddel og forstærker af antitumorvirkning
SI3370733T1 (sl) Postopek za aktivacijo CD40 in blokada imunske nadzorne točke
PL3337506T3 (pl) Kombinacje i ich zastosowania
DK3507453T3 (da) Forbedringer af eller i forbindelse med geotermiske kraftværker
PL3504010T3 (pl) Układ wtrysku termicznego i sposób użycia
EP3473832A4 (en) TURBINE AND TURBOCHARGER